179107-64-3

Upstream product

• 179107-69-8 Trifluoro-methanesulfonic acid 3-biphenyl-4-ylmethyl-4-oxo-chroman-7-yl ester 
• 3218-36-8 4-Phenylbenzaldehyde 
• 151884-08-1 4-oxochroman-7-yl trifluoromethanesulfonate 
• 179107-86-9 Trifluoro-methanesulfonic acid 3-[1-biphenyl-4-yl-meth-(E)-ylidene]-4-oxo-chroman-7-yl ester 

Downstream Products

• 1027405-66-8 1-{(3S,4R)-3-Biphenyl-4-ylmethyl-4-[(S)-2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyloxy]-chroman-7-yl}-cyclopentanecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists

PCT No. PCT/IB95/00401 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/11920 PCT Pub. Date Apr. 25, 1996This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfuslon injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.

Tetrahydronaphthalene and tetrahydroquinoline compounds, their preparation and their use as leukotriene B4(LTB4) antagonists

This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.